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We thanks Matias-Guiu and collaborators for their interesting comments regarding 
our recent article entitled “Dynamic imaging of individual remyelination profiles in MS” 
(1). We had previously showed that both stilbene (2) and benzothiazole derivatives 
(3) could be applied to image myelin by PET in the CNS. The proof of concept clinical 
study we have performed indicates that this imaging approach is relevant in the 
context of multiple sclerosis to quantify myelin loss and repair, an objective that 
remained a major unmet need in this disease.  
 
The interpretation of our results should not be limited to the context of acute clinical 
relapses, as the occurrence of an acute clinical relapse within the month before the 
baseline visit was one of the exclusion criteria for this study. However, all included 
patients  presented a relapsing-remitting form of the disease (RRMS), with at least 
one gadolinium-enhancing lesion on the baseline MRI scan; this hallmark was 
hypothesized to be associated with ongoing, more active demyelination, hence with 
more dynamic endogenous remyelination that might be detected by PET. 
Interestingly, Matias-Guiu and collaborators, using the stilbene derivative 18F-
florbetaben and a semi-quantitative approach, found a lower uptake in the 
progressive types of MS compared to RRMS, suggesting that disease progression 
may be associated with a persistent and cumulative process of myelin loss in the 
white matter (4).  
 
The key remaining question is whether the individual remyelination profiles that were 
detected using 11C-PIB PET have the potential to influence the long-term disease 
evolution. The population investigated had a 7.45 years mean disease duration, and 
the remyelination profiles were highly correlated with disability. In particular, a strong 
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correlation was found between the index of dynamic remyelination and the MS 
severity scale scores, that take into account the disease duration: this suggests that 
remyelination significantly influenced the accrual of medium-term disability during the 
RRMS phase. In order to establish the relationship with disability in the long-term, it 
will be necessary to further follow-up subjects, and to develop similar longitudinal 
studies in the later stages of the disease, especially over the course of progressive 
MS. 
 
The uptake of the tracer in inflammatory conditions has been questioned, and in the 
context of cerebral amyloid angiopathy Carmona-Iragui et al (5) described a milder 
amyloid uptake in swollen areas. Contrasting with this finding, we showed a milder 
uptake reduction in gadolinium enhancing inflammatory lesions compared to overall 
T2 lesions. Therefore in MS, which is a non-amyloid disease, the inflammatory 
component does not seem to negatively bias the estimation of the myelin bound 
fraction. Furthermore, any bias linked to active lesions was minimized, as only 4% of 
the T2 lesional volume analysed by Bodini et al (1) was made of gadolinium 
enhancing lesions.  
 
Finally we carefully quantified the 11C-PIB binding in the normal appearing white 
matter of patients and found no difference with the white matter of control subjects. 
This contrasts with the report of Matias-Guiu et al that described a reduced uptake in 
the NAWM, a difference that could be explained by the inclusion of progressive 
patients in their cohort (7 among 12 patients). It would be of potential clinical interest 
to use the level of tracer binding the NAWM to discriminate RRMS from progressive 
MS. However, some methodological issues may have influenced Matias-Guiu’s 
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findings. Firstly,  in their study, only 3 subjects were included as healthy controls. 
Secondly, Matias-Guiu’s study was not conducted with dynamic acquisitions, as only 
static standardized uptake values (SUVs) were employed to measure 18F-florbetaben 
uptake: this could represent a limit in the interpretation of the results, as it has been 
well shown for 11C-PIB that using SUVs leeds to a higher inter-subject variability and 
less reproducibility (6). Finally, in our study, peri-lesional regions were excluded from 
the NAWM analysis, as 11C-PIB binding in those regions was significantly reduced 
compared to NAWM. It would be therefore of great interest to confirm Matias-Guiu’s 
results after the exclusion of perilesional regions from the NAWM   
 
Overall the application to MS of PET imaging with either stilbene or benziothiazole 
derivatives, especially those that may be labelled with fluorine-18, is indeed a 
promising emerging field of research that may extend the investigations to larger 
cohorts and improve our understanding of the disease physiopathology. Ultimately, 
this approach will allow the evaluation of candidate drugs aimed at promoting 
remyelination.  
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